PHAT News and Press, Phathom Pharmaceuticals Inc. From 08/21/23

Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf life Submission of six-month stability data satisfies Phathom's stability data submission requirements for...

2023-08-10 12:23:37 ET Phathom Pharmaceuticals press release ( NASDAQ: PHAT ): Q2 GAAP EPS of -$0.84 beats by $0.14 . As of June 30, 2023, cash and cash equivalents were $248.8 million. For further details see: Phathom Pharmaceuticals GAAP EPS of -$0.84 beats...

Prior Approval Supplement (PAS) for VOQUEZNA ® TRIPLE PAK ® and VOQUEZNA ® DUAL PAK ® assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 30, 2023 by the U.S. Food and Drug Administration (FDA) U.S. commercial launch for H. pylori ...

2023-08-07 14:34:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the safest sectors on the market is biotech. After all, we can’t stop people from aging — at least not yet. We have millions of people retiring and demanding better care. T...

2023-07-14 16:12:22 ET Summary Phathom Pharmaceuticals, Inc. is trading near 52-week highs. Despite its potential, there are reasons, like a competitive market, why we should take profits on Phathom Pharmaceuticals. If it falls back without major negative reasons before approv...

Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of the sale of an additional 1,668,750 shares of co...

2023-05-24 05:04:27 ET Biopharmaceutical company, Phathom Pharmaceuticals ( NASDAQ: PHAT ) slides 8% as it prices ~11.13M shares at a price to the public of $11.75 per share. The gross proceeds are expected to be ~$130.7M. Underwriters have a 30-day option to purch...

2023-05-23 17:37:45 ET Phathom Pharmaceuticals ( NASDAQ: PHAT ) on Tuesday said it had resubmitted its new drug application (NDA) for its acid suppressant vonoprazan to the U.S. Food and Drug Administration (FDA). The company resubmitted the vonoprazan NDA for the trea...

2023-05-23 17:14:55 ET Gainers: Reata Pharmaceuticals ( RETA ) +10% . Urban Outfitters ( URBN ) +7% . COMPASS Pathways   ( CMPS ) +6% . Stitch Fix ( SFIX ) +5% . TScan Therapeutics ( TCRX ) +4% . Losers: PTC The...